University of California San Francisco
Give to UCSFDean Mary Anne Koda-Kimble, “a major force in shaping, advocating and expanding clinical pharmacy practice in the U.S. and around the world,” will receive the highest honor from the American Pharmacists Association.
New UCSF clinical trial tests intermittent high-dosage treatment for HER2-positive breast cancers.
A panel of experts appointed by Mayor Gavin Newsom recently presented an action plan as the approaching “age wave may bring a potential crisis in Alzheimer’s and dementia care” to San Francisco.
UCSF nephrologist Flavio Vincenti, MD, is the lead author of a paper in the March 2010 issue of the <i>American Journal of Transplantation</i> that reports results from a Phase III clinical trial for a new drug that selectively blocks immune suppression for kidney transplants. The drug, belatacept, is given to kidney-transplant recipients to prevent the immune system from rejecting the new organ. Vincenti and his co-investigators found that belatacept may be as effective as the commonly used anti-rejection drug cyclosporine, but with fewer side effects and superior kidney function after 12 months.
Researchers, who are interested in taking their research from the bench to the bedside, are encouraged to apply for a catalyst award by March 1.
UCSF Chancellor Susan Desmond-Hellmann outlines a vision for faster development of better, cheaper drugs to fight cancer.
The chancellor and other panelists recently shared what they’ve learned from their experiences as both mentor and mentee.
Some of the leading scientists in bioengineering, nanotechnology and pharmaco-genomics will gather on Tuesday, January 26, 2010 to discuss how to harness the tools of these emerging fields to develop new diagnostics and treatments for complex diseases.
The UCSF School of Pharmacy’s Medication Management Program in Fresno will be offering free consultations with professional clinical pharmacists on two consecutive Tuesdays in January. The service is free of charge and open to anyone with diabetes, those who take blood thinners or people taking three or more medications.
Sleeping pill sales have increased dramatically in the past year — in part due to hundreds of millions of dollars spent on direct advertising to consumers.